190 related articles for article (PubMed ID: 31412145)
1. Effect of sitagliptin on tubulointerstitial Wnt/β-catenin signalling in diabetic nephropathy.
Ren X; Zhu R; Liu G; Xue F; Wang Y; Xu J; Zhang W; Yu W; Li R
Nephrology (Carlton); 2019 Nov; 24(11):1189-1197. PubMed ID: 31412145
[TBL] [Abstract][Full Text] [Related]
2. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W
Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747
[TBL] [Abstract][Full Text] [Related]
3. Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway.
Li J; Shu L; Jiang Q; Feng B; Bi Z; Zhu G; Zhang Y; Li X; Wu J
Ren Fail; 2024 Dec; 46(1):2347462. PubMed ID: 38832497
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-27a targets Sfrp1 to induce renal fibrosis in diabetic nephropathy by activating Wnt/β-Catenin signalling.
Shi M; Tian P; Liu Z; Zhang F; Zhang Y; Qu L; Liu X; Wang Y; Zhou X; Xiao Y; Guo B
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32484208
[TBL] [Abstract][Full Text] [Related]
5. Effects of soybean isoflavones on Wnt/β-catenin and the TGF-β1 signaling pathway in renal tissue of type 2 diabetic rats.
Liu CL; Yan L; Cai KR; Sun K; Qi Y; Han YL; Zhang XD; Sun XD
J Biol Regul Homeost Agents; 2018; 32(3):455-464. PubMed ID: 29921370
[TBL] [Abstract][Full Text] [Related]
6. Effect of activin A on tubulointerstitial fibrosis in diabetic nephropathy.
Ren XJ; Guan GJ; Liu G; Zhang T; Liu GH
Nephrology (Carlton); 2009 Apr; 14(3):311-20. PubMed ID: 19298640
[TBL] [Abstract][Full Text] [Related]
7. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R
Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA is superior to paricalcitol in ameliorating tubulointerstitial fibrosis through regulation of VDR/Wnt/β-catenin pathway in rats with diabetic nephropathy.
Zeng JY; Wang Y; Hong FY; Miao M; Jiang YY; Qiao ZX; Wang YT; Bao XR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3959-3977. PubMed ID: 37991543
[TBL] [Abstract][Full Text] [Related]
9. Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway.
Wang D; Zhang G; Chen X; Wei T; Liu C; Chen C; Gong Y; Wei Q
Int J Mol Med; 2018 May; 41(5):2784-2792. PubMed ID: 29484381
[TBL] [Abstract][Full Text] [Related]
10. Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy.
Zhou T; He X; Cheng R; Zhang B; Zhang RR; Chen Y; Takahashi Y; Murray AR; Lee K; Gao G; Ma JX
Diabetologia; 2012 Jan; 55(1):255-66. PubMed ID: 22016045
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression.
Wang J; Hu L; Chen Y; Fu T; Jiang T; Jiang A; You X
Endocrine; 2019 Jan; 63(1):70-78. PubMed ID: 30128961
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.
Huang L; Lin T; Shi M; Chen X; Wu P
Am J Physiol Renal Physiol; 2020 Sep; 319(3):F458-F468. PubMed ID: 32715762
[TBL] [Abstract][Full Text] [Related]
14. Curcumin Rescues Diabetic Renal Fibrosis by Targeting Superoxide-Mediated Wnt Signaling Pathways.
Ho C; Hsu YC; Lei CC; Mau SC; Shih YH; Lin CL
Am J Med Sci; 2016 Mar; 351(3):286-95. PubMed ID: 26992258
[TBL] [Abstract][Full Text] [Related]
15. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice
Li L; Lian X; Wang Z; Zheng J; Liu J; Chu Y; Teng Y; Zhang Z
Pharmazie; 2019 Apr; 74(4):239-242. PubMed ID: 30940309
[TBL] [Abstract][Full Text] [Related]
16. The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats.
Abdelrahman AM; Suleimani YA; Za'abi MA; Ashique M; Manoj P; Hartmann C; Nemmar A; Schupp N; Ali BH
Biomed Pharmacother; 2019 Feb; 110():667-676. PubMed ID: 30553193
[TBL] [Abstract][Full Text] [Related]
17. Sustained Wnt/β-catenin signaling rescues high glucose induction of transforming growth factor-β1-mediated renal fibrosis.
Ho C; Lee PH; Hsu YC; Wang FS; Huang YT; Lin CL
Am J Med Sci; 2012 Nov; 344(5):374-82. PubMed ID: 22270399
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F
Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin ameliorates diabetic nephropathy by upregulating renal nephrin and podocin expression through modulation of adipokines levels.
Ashraf A; Akhtar T; Shabbir A; Aftab U; Shahzad M
Fundam Clin Pharmacol; 2023 Jun; 37(3):549-555. PubMed ID: 36594370
[TBL] [Abstract][Full Text] [Related]
20. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Jo CH; Kim S; Park JS; Kim GH
Kidney Blood Press Res; 2018; 43(3):987-999. PubMed ID: 29913457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
